Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis
about
Nanosizing of drugs: Effect on dissolution rateUptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries.In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii.Antiparasitic agent atovaquoneNanosuspension: An approach to enhance solubility of drugsNanosuspensions: a promising drug delivery strategy.Current advances in sustained-release systems for parenteral drug delivery.Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine modelAtovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.Nanoparticles containing insoluble drug for cancer therapy.Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications.Solid Lipid Nanoparticles of Atovaquone Based on 2(4) Full-Factorial Design.SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.Preventive effect of pidotimod on reactivated toxoplasmosis in mice.The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis.A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier.Increasing Possibilities of Nanosuspension
P2860
Q26781058-01D99BF2-BE5A-44FD-A746-39A6C19F9B78Q33495327-C08E5E84-FA45-4CBE-9263-3AE03E3E9D2BQ33558897-BFEFD763-4913-486C-9641-329CAD7EF914Q34107885-4C91B7BC-B52F-4A7C-B276-6B702C89D14FQ35554511-DD48ACB4-0332-4CCA-830D-553A303AE083Q35826447-7FF55F44-8F5F-4951-8152-A60BA9AA865AQ36316931-03F5B604-EE4A-42EB-B1B9-D57717831E3AQ37392848-7A62147C-D64D-4E5E-878E-85C660247926Q37625142-A7BFED79-36AA-4F12-9B55-E1FCB7AB289DQ37693046-A9E12D5B-A0CA-49D0-9669-B8FCF9C6D633Q39287046-7AC0D485-EA74-459E-86FD-F304B7952CF6Q42087508-2CEE8C53-AEB1-4B2C-9753-246E29F6DAE6Q44164523-CE013A33-E105-4132-BBAB-3DBF4415EEDEQ44499695-43FD2A45-A17B-4734-B110-BD4C58C3E220Q46102626-A24057AE-9226-4791-ACB7-30505CDB59C4Q55687695-2109E7AC-34F1-447A-AC42-3C1662024E57Q59019148-BDAFD446-884B-4ACA-9F5F-BBEEA48C72BD
P2860
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Atovaquone nanosuspensions sho ...... l of reactivated toxoplasmosis
@ast
Atovaquone nanosuspensions sho ...... l of reactivated toxoplasmosis
@en
Atovaquone nanosuspensions sho ...... l of reactivated toxoplasmosis
@nl
type
label
Atovaquone nanosuspensions sho ...... l of reactivated toxoplasmosis
@ast
Atovaquone nanosuspensions sho ...... l of reactivated toxoplasmosis
@en
Atovaquone nanosuspensions sho ...... l of reactivated toxoplasmosis
@nl
prefLabel
Atovaquone nanosuspensions sho ...... l of reactivated toxoplasmosis
@ast
Atovaquone nanosuspensions sho ...... l of reactivated toxoplasmosis
@en
Atovaquone nanosuspensions sho ...... l of reactivated toxoplasmosis
@nl
P2093
P2860
P1476
Atovaquone nanosuspensions sho ...... l of reactivated toxoplasmosis
@en
P2093
O Liesenfeld
R H Müller
P2860
P304
P356
10.1128/AAC.45.6.1771-1779.2001
P407
P577
2001-06-01T00:00:00Z